PCVX
Price:
$111.58
Market Cap:
$12.45B
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc....[Read more]
Industry
Biotechnology
IPO Date
2020-06-12
Stock Exchange
NASDAQ
Ticker
PCVX
According to Vaxcyte, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -23.79. This represents a change of 60.21% compared to the average of -14.85 of the last 4 quarters.
The mean historical PE Ratio of Vaxcyte, Inc. over the last ten years is -15.42. The current -23.79 PE Ratio has changed 15.33% with respect to the historical average. Over the past ten years (40 quarters), PCVX's PE Ratio was at its highest in in the June 2020 quarter at -4.59. The PE Ratio was at its lowest in in the September 2020 quarter at -29.89.
Average
-15.42
Median
-15.17
Minimum
-23.88
Maximum
-5.41
Discovering the peaks and valleys of Vaxcyte, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 319.80%
Maximum Annual PE Ratio = -5.41
Minimum Annual Increase = -35.30%
Minimum Annual PE Ratio = -23.88
Year | PE Ratio | Change |
---|---|---|
2023 | -15.17 | 16.84% |
2022 | -12.98 | 5.18% |
2021 | -12.34 | -20.13% |
2020 | -15.45 | -35.30% |
2019 | -23.88 | 5.19% |
2018 | -22.70 | 319.80% |
The current PE Ratio of Vaxcyte, Inc. (PCVX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-13.50
5-year avg
-15.96
10-year avg
-15.42
Vaxcyte, Inc.’s PE Ratio is less than Larimar Therapeutics, Inc. (-8.80), less than Syndax Pharmaceuticals, Inc. (-6.17), less than Merus N.V. (-18.45), less than Sutro Biopharma, Inc. (-2.69), greater than Arcellx, Inc. (-70.75), less than Ventyx Biosciences, Inc. (-0.89), greater than Immunocore Holdings plc (-27.58), less than DICE Therapeutics, Inc. (-23.17), greater than Nuvalent, Inc. (-32.10), less than Viridian Therapeutics, Inc. (-3.95), greater than Legend Biotech Corporation (-30.94), less than Apellis Pharmaceuticals, Inc. (-15.28), less than Travere Therapeutics, Inc. (-5.83), less than Akero Therapeutics, Inc. (-8.95), less than BioMarin Pharmaceutical Inc. (62.30), less than Liquidia Corporation (-6.20), less than Bio-Techne Corporation (67.14),
Company | PE Ratio | Market cap |
---|---|---|
-8.80 | $513.64M | |
-6.17 | $1.63B | |
-18.45 | $3.41B | |
-2.69 | $337.69M | |
-70.75 | $3.83B | |
-0.89 | $153.35M | |
-27.58 | $1.67B | |
-23.17 | $2.27B | |
-32.10 | $5.59B | |
-3.95 | $900.21M | |
-30.94 | $9.90B | |
-15.28 | $5.00B | |
-5.83 | $839.88M | |
-8.95 | $1.83B | |
62.30 | $16.01B | |
-6.20 | $698.44M | |
67.14 | $11.34B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Vaxcyte, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Vaxcyte, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Vaxcyte, Inc.'s PE Ratio?
How is the PE Ratio calculated for Vaxcyte, Inc. (PCVX)?
What is the highest PE Ratio for Vaxcyte, Inc. (PCVX)?
What is the 3-year average PE Ratio for Vaxcyte, Inc. (PCVX)?
What is the 5-year average PE Ratio for Vaxcyte, Inc. (PCVX)?
How does the current PE Ratio for Vaxcyte, Inc. (PCVX) compare to its historical average?